Original Research Article

Comparison of efficacy between levosalbutamol and levosalbutamol-ipratropum nebulization in mild to moderate childhood asthma

R. Ramanathan, B. Mahalakshmi*

Department of Pediatrics, Rajah Muthiah Medical College and Hospital, Chidambaram, Tamil Nadu, India

Received: 14 February 2019
Revised: 14 June 2019
Accepted: 10 July 2019

*Correspondence:
Dr. B. Mahalakshmi,
E-mail: drvinothp@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The objective of the study was to compare the efficacy between levosalbutamol and ipratropium combination over levosalbutamol nebulisation in reversing airflow obstruction and improve oxygenation, evaluated using the pulmonary asthma score, SaO2, and PEFR in mild and moderate asthma.

Methods: A prospective, randomized, study was performed in RMMCH pediatric emergency department. Children between 6 and 12 years of age who presented with mild to moderate asthma exacerbations were enrolled in the study. They were randomly allocated into two different groups: one nebulised with levosalbutamol alone and another with addition of ipratropium bromide to levosalbutamol. Baseline Peak expiratory flow rate and Final absolute values or change from baseline 60-120 minutes after the inhalation are measured. Patients were evaluated using the pulmonary score.

Results: After treatment there is improvement in the mean pulmonary asthma scores and PEFR percentage in A+B group than A group, but it is not statistically significant (p value >0.05). There is statistically significant improvement in pulmonary asthma score and PEFR in each of the groups after nebulisation and pulmonary asthma score has a sensitivity of 66.7% and 65.6% in diagnosing severity of asthma in relation to PEFR.

Keywords: Ipratropium bromide, Levosalbutamol, Peak expiratory flow rate, Pulmonary asthma score

INTRODUCTION

Asthma is a common chronic inflammatory disorder of the airways associated with airway hyper responsiveness. Asthma exacerbation is defined as an acute or subacute deterioration of symptom control that causes distress or risks health to the extent that a visit to a health care provider or treatment with systemic corticosteroids becomes necessary. The most common trigger for asthma exacerbation in both younger and older children are viral respiratory tract infections. The other typical factors are exposure to allergens and a suboptimal control of asthma as a baseline.5 Acute exacerbations are a frequent cause of emergency department visits.3,4 Children with acute asthma exacerbations frequently present to an emergency department with signs of respiratory distress. The most severe episodes are potentially life threatening. Effective treatment depends on the accurate and rapid assessment of disease severity at presentation. The use of evidence-based asthma guidelines can improve outcomes for children with asthma.5

The initial management of acute asthma exacerbations in children focuses on the rapid relief of bronchospasm with inhaled or nebulised bronchodilators.6,7
The administration of β2 agonists is the crucial element of therapy in status asthmaticus.9 Children who are not responsive to bronchodilators require the addition of glucocorticoids.9,10 Beta2 agonists are the most effective of the bronchodilators owing to their rapid onset of action and the extent of achieved bronchodilation.11,12 Anticholinergic agents, such as ipratropium bromide and atropine sulphate have a slower onset of action and weaker bronchodilating effect than beta2 agonists but may relieve cholinergic bronchomotor tone and decrease mucosal edema and secretions.13,14 Thus the combination of inhaled anticholinergics with beta2 agonists may yield enhanced and prolonged bronchodilation.

Several randomized controlled trials have examined the efficacy of the addition of anticholinergics to beta2 agonists for treating acute asthma in children.15,16 Conflicting results from these trials were attributed to differences in the severity of the asthma, intensity(number of doses) of anticholinergic treatment,cointervention with glucocorticoids and study power.17 Though current guidelines recommends the use of anticholinergics in acute severe or life threatening asthma, its role in mild to moderate asthma exacerbation is still inconclusive.

METHODS

A prospective, randomized, study was performed in RMMCH pediatric emergency department between the months of August 2016 and August 2018. The study was previously approved by the hospital ethics committee. Children between 6 and 12 years of age who presented with mild to moderate asthma exacerbations were enrolled in the study. They were randomly allocated into two different groups: one nebulised with levosalbutamol alone and another with addition of ipratropium bromide to levosalbutamol. Baseline Peak expiratory flow rate and Final absolute values or change from baseline 60–120 minutes after the inhalation were measured. Because the peak bronchodilator effect after the administration of anticholinergics occurs within 1-2 hours, it is reasonable to expect significant improvement during this time. Patients were evaluated using the pulmonary score.18 The oxygen saturation (SaO2) was measured using a pulse oximeter. Peak expiratory flow rate was performed using a portable peak flow meter. The predicted PEF was adjusted for sex and height and the percentages of the PEFR before and after nebulisation was obtained.19,20

The severity of the asthma crisis was classified according to the pulmonary asthma score as mild (score 5-7and PEF >70% of the predicted value according to the age and sex); moderate (score 8-11) and PEF 50-70% or FEV1 60-80% of the predicted value) and severe (score 12-15) and PEF <50% or FEV1 <60% of the predicted value). The pulmonary asthma score was the main criteria to rank severity of asthmatic crisis.

| Component score | 0 | 1 | 2 | 3 |
|-----------------|---|---|---|---|
| Respiratory rate | 14-20 | 21-26 | 27-30 | >31 |
| Oxygen saturation | >98% at room air | 95-97% on room air | 90-94% on room air | <90% on room air |
| Auscultation | Normal breath sounds | End expiratory wheezing | Expiratory wheezing | Inspiratory and expiratory wheeze |
| Retractions | None | Intercostal | Intercostal and substernal | Intercostal and substernal and supraclavicular |
| Dyspnea | Speaks in complete sentences | Speaks in short sentences, coos, and babbles | Speaks in partial sentences, short cry | Speaks in single words, short phrase/grunting |

RESULTS

Group A- levosalbutamol

Group A+B - levosalbutamol + ipratropium bromide.

Out of 50 children participated in the study, 25 children were allotted to A group and 25 children were allotted to A+B group. Out of 50 children, 37 children were above 8 years of age and 13 children were less than 8 years of age.

Children were classified based on the severity of asthma exacerbation at the time of presentation as mild and moderate exacerbation using a clinical scoring system, Pulmonary asthma score. Based on PAS classification of disease severity, both groups contained an equal proportion of mild and moderate cases before nebulisation. Hence two groups were adequately matched based upon severity of exacerbation.

Comparison of heart rate before and after nebulisation indicates that there is no significant tachycardia following
nebulisation. There is improvement in respiratory rate and oxygen saturation in both groups following nebulisation. And also there is a significant improvement in PAS and PEFR after nebulisation with both the treatment regimes.

Table 2: Age group and name of the medication used cross tabulation.

| Age range | Name of the medication used | Total | P value |
|-----------|-----------------------------|-------|---------|
|           | A                           | A+B   |         |
| 6-8 yrs   | 8                           | 5     | 13      | 0.260 |
| >8 yrs    | 17                          | 20    | 37      |       |
| Total     | 25                          | 25    | 50      |       |

Table 3: Comparison of pulmonary asthma score before nebulisation in two groups.

| PAS classification | Name of the medication used | Total | P value |
|--------------------|-----------------------------|-------|---------|
|                    | A                           | A+B   |         |
| Mild               | 10                          | 8     | 18      |       |
| Moderate           | 15                          | 17    | 32      | 0.509 |
| Total              | 25                          | 25    | 50      |       |

Table 4: Comparison of asthma severity based on baseline PEFR between two groups.

| Name of the Medication Used | Total | P value |
|-----------------------------|-------|---------|
| A                           | A+B   |         |
| Pefr %                      |       |         |
| Mild                        | 10    | 8       | 18      | 0.384 |
| Moderate                    | 15    | 17      | 32      |       |
| Total                       | 25    | 25      | 50      |       |

There is no significant difference in PEFR after nebulisation between A+B and A group. Hence the addition of ipratropium bromide nebulisation doesn’t significantly improve PEFR than the levosalbutamol alone group.

There is no significant difference in improvement of PAS after nebulisation between A+B group and A group. Hence the addition of ipratropium bromide nebulisation doesn’t significantly improve PAS than the levosalbutamol alone group.

Table 5: Comparison of means of HR, RR, SPO2, PAS and PEFR before and after nebulization.

|                 | N  | Mean | Std. deviation  |
|-----------------|----|------|-----------------|
| Before          |    |      |                 |
| B-HR            | 50 | 130.84 | 23.191         |
| B-RR            | 50 | 35.74  | 8.799          |
| B-SPO2          | 50 | 94.5000% | 3.01865%     |
| B-PAS           | 50 | 6.52  | 2.443          |
| B-PEFR          | 50 | 65.6800% | 9.29437%     |
| After           |    |      |                 |
| A-HR            | 50 | 128.40 | 23.181         |
| A-RR            | 50 | 29.44  | 7.843          |
| A-SPO2          | 50 | 96.2800% | 2.57967%     |
| A-PAS           | 50 | 4.54  | 2.451          |
| A-PEFR          | 50 | 77.8200% | 7.93003%     |

According to PEFR before nebulisation, 18 patients had mild and 32 had moderate exacerbations and there is no significant differences in severity in both groups based on PEFR. Hence PEFR grading correlates with asthma severity based on PAS.

Table 7: Comparison of mean PEFR after nebulisation in two groups.

| Name of the medication used | N   | Mean   | Std. deviation   | T value | P value |
|-----------------------------|-----|--------|------------------|---------|---------|
| % of Predicted PEFR after neb | A   | 25     | 77.1600%        | 8.80663% | 0.562  |
| A+B                         | 25  | 78.4800% | 7.06588%        |         |         |
DISCUSSION

Both groups were matched for age, sex, oxygen saturation and asthma severity. Based on PEFR, out of 50 children, 36% had mild exacerbation and 64% had moderate exacerbation of asthma respectively.

Chi square test was used for statistical analysis, paired and unpaired T test were used for comparison between two groups.

There is statistically significant improvement in pulmonary asthma score and PEFR in each of the groups after nebulisation and pulmonary asthma score has a sensitivity of 66.7% and 65.6% in diagnosing severity of asthma in relation to PEFR. After nebulisation there is significant improvement in respiratory rate and oxygen saturation in each of the groups but there is not much difference between two groups.

After treatment there is improvement in the mean pulmonary asthma scores and PEFR percentage in A+B group than A group, but it is not statistically significant (p value >0.05). This may be attributed to small sample size in both groups. Yet the effects of Ipratropium with levosalbutamol seems to be equal to the levosalbutamol alone group.

In a study of 125 children with severe asthma, by Quershi et al, found that (FEV1) improved to a greater extent in children receiving salbutamol and ipratropium than in those receiving salbutamol placebo, but there is no effect on overall rates of hospitalisation. In a subgroup analysis of children in whom FEV1 was less than 30 percent of the predictive value, the hospitalisation rate among those receiving the combination therapy was significantly lower than the rate with salbutamol alone.21

In a study of 434 children by Schuh et al with moderate and severe asthma exacerbation showed that the addition of ipratropium bromide had a significant effect on improvement of asthma score, but there was no significant improvement of PEFR.22

In a study done in India by Sharma A et al in 2004 showed that frequent combined nebulisation with salbutamol and ipratropium significantly improved percentage of PEFR starting at 30 minutes and lasting for 4 hours in 50 children (6-14years) with moderate exacerbation.23

Ricardo Iraiman et al.24 In their study found that Ipratropium +Salbutamol group presented a significantly greater improvement in clinical parameters (PAS+SPO2) and in lung function (PEFR) than children in salbutamol group. But this study differed from our study in including children with moderate to severe asthma crisis. In our study acute severe asthma cases were excluded due to their inability to perform peak expiratory flow and forceful expiration may aggravate bronchospasm.

In a study of 298 participants by Francine et al, showed that no increased bronchodilation was associated with addition of ipratropium bromide compared to placebo. No group differences were observed in oxygen saturation, corticosteroid use, patient disposition and relapse status.25

In a study of 477 children by Joseph J. Zorc et al, ipratropium group subjects had 13% shorter treatment time and required fewer total albuterol doses, but admissions rates did not differ significantly.26

CONCLUSION

Ipratropium combination therapy has a definitive role in severe asthma crisis. But its role in mild to moderate asthma exacerbation is still inconclusive. Statistical significance has not been obtained in our study due to relatively smaller number of cases in each group. Pulmonary asthma score holds good in assessing the severity of asthma exacerbation and hence can be used for rapid clinical evaluation of acute asthma in emergency settings and also to assess the response to treatment and to decide on hospital admission.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. From the Global strategy for the diagnosis and management of Asthma in Children 5 years and younger, Global initiative for Asthma. GINA; 2009. Available at: www.ginasthma.org (Accessed 18 May 2011).
2. Bloomberg GR. The exacerbation component of impairment and risk in pediatric asthma. Curr Opin Allergy Clin Immunol. 2010;10(2):155-60.
3. Guttmann A, Zagorski B, Austin PC, Schull M, Razaq A, To T, et al. Effectiveness of emergency department asthma management strategies on return visits in Children: A pediatric population based study. Pediatr. 2007 Dec 1;120(6):e1402-10.
4. Rosychuk RJ, Voklander DC, klassen TP, Senthilselvan A, Marrie TJ, Rowe BH. Asthma presentations by children to emergency departments in a Canadian province: A population based study. Pediatr Pulmonol. 2010;45(10):985-92.
5. Cunningham S, Logan C, Lockerbie L, Dunn MJ, McMurray A, Prescott RJ. Effect off an integrated care pathway on acute asthma/wheeze in children attending hospital, Cluster randomized trial. J Pediatr. 2008;152(3):315-20.
6. British medical association. Asthma: a follow up statement from an international pediatric asthma group. Arch Dis Child. 1992;67:240-8.

7. Ernst P, Fitzgerald JM, Spier S. Canadian asthma consensus conference summary of recommendations. Can Respir J. 1996;3(2):89-101.

8. Werner HA. Status asthmaticus in children. Chest 2001;119:1913-29.

9. Tal A, Levy N, Bearman JE. Methyl prednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatr. 1990 Sep 1;86(3):350-6.

10. Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatr. 1993 Oct 1;92(4):513-8.

11. Svedmyr N. Fenoterol: A beta 2 agonist for use in asthma pharmacology and pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. J Huma Pharmacol Drug Ther. 1985 May 6;5(3):109-26.

12. Sears MR. Clinical application of beta agonists, practical allergy Immunol. 1992;7:98-100.

13. Gross NJ. Ipratropium bromide. N Engl J Med. 1988 Aug 25;319(8):486-94.

14. Chapman K. An international perspective on anticholinergic therapy. Am J Med. 1996 Jan 29;100:S2-4.

15. Guili MF, Maloney MJ, Durant RH. Comparison of inhaled metaproterenol, inhaled atropine sulfate, and their combination in treatment of children with acute asthma Ann Allergy. 1987 Nov;59(5):367-71.

16. Watson WTA Becker AB, Simsons FER. Comparison of ipratropium solution, F Eneterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. J allergy Clin Immunol. 1988 Dec 1;82(6):1012-8.

17. Ossmand MH Klassen TP. Efficacy of ipratropium in acute childhood asthma a meta analysis. Acad Emerg Med. 1995 Jul;2(7):651-6.

18. Smith SR, Baty JD, Hodge DIII. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med. 2002 Feb;9(2):99-104.

19. Fuhlbrigge AL, Weiss ST Kuntz KM, David Paltiel A. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics. 2006 Aug 1;118(2):e347-55.

20. MAKING SENSE of Lung Function Tests. Second edition. A hands-on guide Jonathan Dakin, MD FRCP BSc Hons, UK Mark Mottershaw, BSc Hons MSc, UK Elena Kourteli, FRCA, UK 2nd ed, Boca Raton, United Kingdom; 2017:224.

21. Quershi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Eng J Med. 1998 Oct 8;339(15):1030-5.

22. Schuh S. Efficacy of frequent nebulised ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatri. 1995 Apr 1;126(4):639-45.

23. Sharma A, Madaan A. Nebulised salbutamol Vs salbutamol and ipratropium combination in asthma. Indian J pediatri. 2004 Feb 1;71(2):121-4.

24. Iramain R, López-Herce J, Coronel J, Spitters C, Guggiari J, Bogado N. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. J Asthma. 2011 Apr 1;48(3):298-303.

25. Ducharme FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma. J Pediatri. 1998 Oct 1;133(4):479-85.

26. Zorc JJ, Pusic MV, Ogborn CJ, Lebet R, Duggan AK. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics. 1999 Apr 1;103(4):748-52.

Cite this article as: R. Ramanathan, B. Mahalakshmi. Comparison of efficacy between levsalbutamol and levsalbutamol-ipratropium nebulization in mild to moderate childhood asthma. Int J Contemp Pediatr 2019;6:xxx-xx.